Abdominal irradiation as a rescue therapy for feline gastrointestinal lymphoma: A retrospective study of 11 cats (2001–2008)

Section: Radiation Protocols and Response To Therapymentioning

confidence: 99%

Feline alimentary lymphoma

Barrs

Beatty

2012

“…The survival time of this cat was the same as the median OST of 11 cats that were treated with two fractions of abdominal radiation after failing chemotherapy. 41 Presently, it is unknown which lymphoma subtypes would benefit most from radiation alone or as a combination therapy.…”

Section: Discussionmentioning

confidence: 99%

Does categorisation of lymphoma subtypes according to the World Health Organization classification predict clinical outcome in cats?

Wolfesberger

Skor

Hammer

et al. 2016

Objectives The purpose of this study was to specify lymphoma subtypes according to the World Health Organization (WHO) classification in a group of cats and to investigate their potential prognostic value. Methods Records of cats from the University of Veterinary Medicine Vienna suffering from lymphoma were reviewed in this retrospective study. To diagnose various subtypes specified in the WHO classification, histopathological and immunohistochemical examinations, as well as clonality assays in some cases, were performed. Results Of the 30 cats included in this study and classified according to the WHO guidelines, peripheral T-cell lymphoma was the most prevalent lymphoma subtype (37% of cases; n = 11), followed by diffuse large B-cell (23%; n = 7), intestinal T-cell (10%; n = 3), T-cell-rich B-cell (10%; n = 3), large granular lymphocytic (7%; n = 2), anaplastic large T-cell (7%; n = 2), B-cell small lymphocytic (3%; n = 1) and T-cell angiotropic lymphoma (3%; n = 1). The median survival time (MST) was 5.4 months (range 6 days to 2.2 years), with two cats still alive after 1.7 and 2.0 years, respectively. Treating cats prior to chemotherapy with glucocorticoids did not worsen their prognosis. Adding to chemotherapy, radiotherapy or surgery did not improve the clinical outcome. We observed that patients with intestinal T-cell lymphoma lived significantly longer (MST 1.7 years) than those with a diffuse large B-cell (MST 4.5 months) or peripheral T-cell lymphoma (MST 6.1 months). Cats with T-cell-rich B-cell lymphoma survived significantly longer (MST 1.2 years) than those with a diffuse large B-cell lymphoma. Conclusions and relevance A detailed diagnosis of feline lymphoma can be obtained by allocating different subtypes according to the WHO classification. From the eight detected lymphoma subtypes, two, intestinal T-cell lymphoma and T-cell-rich B-cell lymphoma, showed promising survival times in cats.

“…14 Our current study had a similar finding of non-large cell cases having a higher response rate and more durable remission durations to their lomustine rescue protocol. Another study by Parshley et al 15 looked at abdominal irradiation as a rescue therapy for feline GI lymphoma and found few, if any, acute effects and a response in 10/11 cats for a median survival of 214 days post-radiation. 15 In this study, the only significant factor affecting survival was body weight.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of lomustine as a rescue agent for cats with resistant lymphoma

Dutelle¹,

Bulman-Fleming

Lewis³

et al. 2012

This retrospective study evaluated the use of lomustine as a rescue agent for 39 cases of resistant feline lymphoma. Parameters assessed included lymphocyte cell size, number of previous chemotherapy drugs and number of previous chemotherapy protocols received, time from lymphoma diagnosis to initiation of lomustine therapy, body weight and anatomic location of lymphoma. Cell size, number of previous chemotherapy drugs, number of previous chemotherapy protocols and anatomic location were all significant prognostic factors for the progression-free interval. Twenty-one cats (54%) received more than one dose of lomustine. The overall median progression-free interval (MPFI) was 39 days (range 7-708 days). The MPFI for large versus small and intermediate cell lymphomas was 21 versus 169 days, respectively. The MPFI for gastrointestinal versus non-gastrointestinal lymphomas was 180 versus 25.5 days, respectively. Lomustine has an acceptable efficacy and safety for use as a rescue agent in feline lymphoma.